NO891191L - Fremgangsmaate for fremstilling av nye, terapeutisk virksomme catecholderivater. - Google Patents

Fremgangsmaate for fremstilling av nye, terapeutisk virksomme catecholderivater.

Info

Publication number
NO891191L
NO891191L NO89891191A NO891191A NO891191L NO 891191 L NO891191 L NO 891191L NO 89891191 A NO89891191 A NO 89891191A NO 891191 A NO891191 A NO 891191A NO 891191 L NO891191 L NO 891191L
Authority
NO
Norway
Prior art keywords
group
derivatives
preparation
therapeutically effective
hydrogen atom
Prior art date
Application number
NO89891191A
Other languages
English (en)
Norwegian (no)
Other versions
NO891191D0 (no
Inventor
Nobuyuki Fukazawa
Kengo Otsuka
Shizuo Shimada
Yukio Miyama
Fumiaki Ikeda
Tatsuo Kaiho
Original Assignee
Mitsui Toatsu Chemicals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP6351588A external-priority patent/JPH0696520B2/ja
Priority claimed from JP63201866A external-priority patent/JPH0720929B2/ja
Application filed by Mitsui Toatsu Chemicals filed Critical Mitsui Toatsu Chemicals
Publication of NO891191D0 publication Critical patent/NO891191D0/no
Publication of NO891191L publication Critical patent/NO891191L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/36—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO89891191A 1988-03-18 1989-03-17 Fremgangsmaate for fremstilling av nye, terapeutisk virksomme catecholderivater. NO891191L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP6351588A JPH0696520B2 (ja) 1988-03-18 1988-03-18 カテコールアミン誘導体を含有してなる中枢性神経退行性疾患の進行防止および治療剤
JP6351688 1988-03-18
JP20186588 1988-08-15
JP63201866A JPH0720929B2 (ja) 1988-08-15 1988-08-15 ジヒドロカフェイン酸アミド化合物およびそれを有効成分として含有する治療剤

Publications (2)

Publication Number Publication Date
NO891191D0 NO891191D0 (no) 1989-03-17
NO891191L true NO891191L (no) 1989-09-19

Family

ID=27464327

Family Applications (1)

Application Number Title Priority Date Filing Date
NO89891191A NO891191L (no) 1988-03-18 1989-03-17 Fremgangsmaate for fremstilling av nye, terapeutisk virksomme catecholderivater.

Country Status (8)

Country Link
EP (1) EP0333522B1 (de)
KR (1) KR910008665B1 (de)
AU (1) AU602628B2 (de)
DE (1) DE68917499T2 (de)
DK (1) DK130389A (de)
FI (1) FI891227L (de)
NO (1) NO891191L (de)
NZ (1) NZ228329A (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD299424A5 (de) * 1989-05-23 1992-04-16 Sankyo Company Limited,Jp Phenolderivate zur foerderung des menschlichen nervenwachstumsfaktors
US5290793A (en) * 1989-09-12 1994-03-01 Mitsui Toatsu Chemicals, Incorporated Dihydrocaffeic acid derivatives and pharmaceutical preparation containing same
JPH0660141B2 (ja) * 1989-09-12 1994-08-10 三井東圧化学株式会社 ジヒドロカフェイン酸誘導体およびそれを有効成分として含有する治療剤
FR2669029B1 (fr) * 1990-11-14 1994-09-02 Adir Nouveaux derives de la n-benzoyl proline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
EP0501656B1 (de) * 1991-02-21 1997-01-22 Sankyo Company Limited Benzolderivate zum Fördern der Produktion des Nervenwachstumsfaktors
US5480907A (en) * 1991-05-16 1996-01-02 Takeda Chemical Industries, Ltd. Aromatic amide compounds and their production and use
CA2103367A1 (en) * 1991-05-20 1992-11-21 Akihide Koda Phellodendrine analogs and allergy type iv suppressor containing the same as active ingredient
US6207665B1 (en) 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
CZ20022720A3 (cs) * 2000-02-11 2002-11-13 Vertex Pharmaceuticals Incorporated Deriváty piperazinu a piperidinu pro pouľití při léčení a prevenci poąkozených neuronů
DE602005015033D1 (de) * 2005-02-28 2009-07-30 Tseti Ioulia Medikamente gegen alzheimer-krankheit
KR100957465B1 (ko) * 2006-08-10 2010-05-14 (주)아모레퍼시픽 히드록시신남산 유도체 화합물과 그 제조방법 및 이를함유하는 화장료 조성물
US8507493B2 (en) 2009-04-20 2013-08-13 Abbvie Inc. Amide and amidine derivatives and uses thereof
MX2011011082A (es) * 2009-04-20 2011-11-04 Abbott Lab Derivados de amida y amidina novedosos y usos de los mismos.
DE102009031342A1 (de) 2009-07-01 2011-01-05 Daimler Ag Verwendung von Schmierölen mit mikrogekapselten Schmierstoffadditiven, Verwendung derselben in Schmierölen für Kraftfahrzeuge mit Verbrennungsmotor und Verbrennungsmotor mit mikrogekapselte Schmierstoffadditive enthaltenden Schmieröl
FR2964866B1 (fr) * 2010-09-22 2013-03-29 Oreal Utilisation comme antipelliculaire de derives ortho-diphenol, nouveaux composes et composition cosmetique les comprenant
US20140221485A1 (en) * 2011-09-06 2014-08-07 Novaliq Gmbh Lipophilic dopamine derivatives and their use
KR101327817B1 (ko) 2012-03-22 2013-11-08 (주)에이씨티 미백 효과를 나타내는 아마이드 유도체의 제조방법 및 상기 아마이드 유도체를 함유하는 화장료 조성물
WO2014139161A1 (en) * 2013-03-15 2014-09-18 Techfields Pharma Co., Ltd. Novel high penetration drugs and their compositions thereof for treatment of parkinson diseases
WO2016090355A2 (en) * 2014-12-05 2016-06-09 Massachusetts Institute Of Technology Catechol-rich polymers from n-substituted maleimides
AU2019256714A1 (en) * 2018-04-20 2020-11-12 The General Hospital Corporation Acetylated prodrugs for delivery across the blood-brain barrier
CN114478296B (zh) * 2022-02-14 2024-07-19 河南旭瑞新材料科技有限公司 一种二氢燕麦生物碱的制备方法
KR20250106753A (ko) 2024-01-03 2025-07-11 건국대학교 글로컬산학협력단 카테콜 유도체가 결합된 담즙산을 포함하는 대사성 질환 예방 및 치료용 약학적 조성물 및 이의 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181738A (en) * 1976-11-30 1980-01-01 Cornell Research Foundation, Inc. Catecholamine derivatives, a process for their preparation and pharmaceutical compositions thereof
US4529604A (en) * 1977-03-28 1985-07-16 Smithkline Beckman Corporation N,N-Di-(n-Propyl)dopamine derivatives
US4424205A (en) * 1982-03-18 1984-01-03 The Procter & Gamble Company Hydroxyphenylacetamides having analgesic and anti-irritant activity
LU85856A1 (fr) * 1984-04-17 1986-06-11 Glaxo Group Ltd Composes de phenethanolamine
US4579866A (en) * 1984-05-29 1986-04-01 Usv Pharmaceutical Corp. Phenylacetamides as anti-allergy, anti-asthma and anti-inflammatory agents
GB2178031B (en) * 1985-06-10 1989-07-26 Procter & Gamble Phenylacetic acid amides having anti-inflammatory and analgesic activity
FI874163L (fi) * 1986-09-26 1988-03-27 Mitsui Toatsu Chemicals Katekolderivat samt preparat innehaollande desamma foer haemmande och botande av regressiva sjukdomar i det centrala nervsystemet.

Also Published As

Publication number Publication date
AU3144389A (en) 1989-09-21
NO891191D0 (no) 1989-03-17
DK130389D0 (da) 1989-03-17
FI891227A7 (fi) 1989-09-19
EP0333522B1 (de) 1994-08-17
EP0333522A2 (de) 1989-09-20
KR890014098A (ko) 1989-10-21
DK130389A (da) 1989-09-19
DE68917499D1 (de) 1994-09-22
KR910008665B1 (ko) 1991-10-19
FI891227L (fi) 1989-09-19
EP0333522A3 (de) 1991-04-17
FI891227A0 (fi) 1989-03-15
DE68917499T2 (de) 1995-02-09
NZ228329A (en) 1991-12-23
AU602628B2 (en) 1990-10-18

Similar Documents

Publication Publication Date Title
NO891191L (no) Fremgangsmaate for fremstilling av nye, terapeutisk virksomme catecholderivater.
MX9707732A (es) Compuestos triciclicos utiles en el tratamiento de desordenes proliferativos de celulas.
CA2212326A1 (en) O-carbamoyl-(d)-phenylalanilol compounds and process for preparing the same
IL108769A0 (en) Spirocyclic piperidine derivatives
AU671933B2 (en) The administration of monoamine acridine in cholinergic neuronal deficit states
MY114132A (en) Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases.
NO962543L (no) Cykliske amid-derivater som neurokinin A-antagonister
AU3060197A (en) Aryl substituted cyclic amines as selective dopamine d3 ligands
NO954453L (no) Nye pyridin-, pyrimidin- og benzenderivater som adreno-ceptorantagonister
NO169346C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 17beta-(cyclopropylamino)androst-5-en-3beta-ol og beslektede forbindelser
FI904035A0 (fi) Menetelmä valmistaa terapeuttisesti aktiivisia 4-substituoituja 17 -(syklopropyyliamino)androst-5-eenijohdannaisia, jotka ovat hyödyllisiä C17-20-lyaasi-inhibiittoreina
ATE205712T1 (de) Verwendung von 2-phenyl-3-aroylbenzothiophen derivaten zur herstellung eines medikaments zur hemmung der angiogenese und angiogene krankheiten
ES464144A1 (es) Procedimiento de preparacion de compuestos derivados de la piperidina.
IL112042A0 (en) Methods of inhibiting seborrhea and acne
ATE142496T1 (de) Verwendung von n-butyl-deoxynojirimycin zur behandlung von herpes
DE68923151D1 (de) Verwendung von Trifluormethylphenyl-Tetrahydropyridinen zur Herstellung von Arzneimitteln zur Behandlung anxio-depressiver Erkrankungen.
DE68908145D1 (de) Verwendung von l-carnitinderivaten zur herstellung eines arzneimittels zur therapeutischen behandlung von peripheren neuropathien.
PT87437A (pt) Product for restoring as well as stimulating and increasing hait growth
DE69209128D1 (de) Verwendung von Indazol-Methoxyalkansäure zur Herstellung eines Arzneimittels zur Behandlung von Autoimmunkrankheiten
EP0244739A3 (en) N-substituted pyrrolidine and piperidine derivatives and their salts
HU9203956D0 (en) Method for producing indole derivatives
DE3867281D1 (de) Calcium-4,6-dioxo-4h-pyrano(3,2-g)-chinolin-2,8-dicarboxylat-derivat, verfahren zu seiner herstellung und dieses enthaltende zusammensetzungen.
DE69620027D1 (de) Verwendung von eliprodil zur herstellung eines arzneimittels zur behandlung von ischämischen störungen der retina oder des sehnervs
NO169391C (no) Analogifremgangsmaate for fremstilling av et terapeutisk aktivt (-)-cis-quinuklidin og syreaddisjonssalter derav
EP0495998A4 (de)